Remarkably, antisense oligonucleotides against BCL2 such as SPC2996, have also been tested in a clinical trial to inhibit BCL2 in CLL (NCT00285103) [203], and ROR1-CART cells are being evaluated for treatment (NCT02706392), further supporting the key role of BCL2 and ROR1 dysregulation in this disease, driven by the loss of miR-15a/miR-16-1. Here, ROR1 is linked to B-cell chronic lymphocytic leukemia.